TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals Limited has announced the quotation of 11,714,207 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of October 8, 2025. This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing development projects, potentially strengthening its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for treating inflammatory diseases. The company is primarily engaged in creating solutions that address unmet medical needs, with a market focus on innovative treatments for conditions such as osteoarthritis and other musculoskeletal disorders.
Average Trading Volume: 899,644
Technical Sentiment Signal: Hold
Current Market Cap: A$144.1M
Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.